Euroapi S.A.S.U. (940)
FSX
Closed
Sep 28, 2026
Day's Range
0.743052 wk Range
0.7240Overview - 940 - Euroapi S.A.S.U.
Key Statistics
Valuation
Enterprise Value
125.97M
P/E (Trailing)
‪9.21‬
Price / Sales (TTM)
‪0.08‬
Price / Book
‪0.14‬
EV / EBITDA
‪0.95‬
Profitability
Profit Margin
‪-40.80%‬
Operating Margin
‪-2.86%‬
Return on Assets
‪-0.93%‬
Return on Equity
‪-39.99%‬
Ownership
Shares Outstanding
95.18M
Float
50.79M
Held by Insiders
‪34.83%‬
Held by Institutions
‪36.01%‬
Price stats
Beta
‪0.95‬
50-Day Avg
‪0.9291‬
200-Day Avg
‪1.43‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 940 - Euroapi S.A.S.U.
Peers - 940 - Euroapi S.A.S.U.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on FSX.
- 940FSXEuroapi S.A.S.U.70.02MMarket Cap-342.84%52-week change9.21P/E (Trailing)‪-40.80%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- PARFSXParker-Hannifin Corporation109.81BMarket Cap+26.04%52-week change35.40P/E (Trailing)‪16.96%‬Profit Margin
- MRKFSXMerck KGaA60.08BMarket Cap+13.03%52-week change25.79P/E (Trailing)‪11.21%‬Profit Margin
- MRKCFSXMerck KGaA – Sponsored ADR58.69BMarket Cap+14.60%52-week change24.77P/E (Trailing)‪11.21%‬Profit Margin
- PY3FSXGalderma Group AG39.87BMarket Cap-1.16%52-week change54.63P/E (Trailing)‪14.57%‬Profit Margin
- 0BOFSXJiangsu Hengrui Pharmaceuticals Co., Ltd.37.83BMarket Cap-75.44%52-week change37.67P/E (Trailing)‪24.93%‬Profit Margin
Profile Summary - 940 - Euroapi S.A.S.U.
About
Euroapi S.A.S.U. is a leading pharmaceutical company specializing in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs) and intermediates for human and veterinary medicines. With approximately 200 products in its portfolio, it offers one of the largest selections in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
